Efferon® LPS is a single-use adsorber for extracorporeal blood purification, designed for the selective adsorption of lipopolysaccharides and the non-selective adsorption of cytokines, myoglobin, and other inflammatory mediators. This solution supports rapid intervention in Gram-negative sepsis, critical endotoxemia, and cytokine storm syndrome.
Sterile, non-pyrogenic, low flow-resistance device; compatible with hemoperfusion, RRT, ECMO and CPB systems.
The device is intended for hemoperfusion in an extracorporeal system, either in direct mode on its own or in combination with other extracorporeal therapy platforms. Timely implementation supports the stabilization of vital functions and limits the progression of multi-organ failure.
Efferon® LPS supports the treatment of severe sepsis patients by removing endotoxins and inflammatory mediators from circulation, reducing the risk of organ failure progression.
Efferon® LPS technology combines selective endotoxin binding with the adsorption of cytokines and other inflammatory mediators. This allows the device to support a more comprehensive therapeutic response than classic, single-dimensional solutions.
The adsorbent surface is modified with a ligand selective for LPS, enabling permanent and irreversible binding of bacterial endotoxins.
The mesoporous polymer structure adsorbs excess cytokines, myoglobin and other molecules associated with the inflammatory response and tissue damage.
The material does not crumble, generate dust, or release organic contaminants, maintaining high biocompatibility and low thrombogenic activity.
The column construction, adsorbent properties and selective ligand work together to ensure stable blood flow and effective removal of key inflammatory mediators.
Our clinical team will get back to you within one business day about products, training or pricing.
